Hematology Xagena

Xagena Mappa
Xagena Newsletter
Medical Meeting

Search results for "Immune thrombocytopenic purpura"

Interim results from an open-label study have shown that long-term administration ( up to 48 weeks ) of its investigational therapy AMG 531 was generally well-tolerated and stimulated platelet product ...

Patients suffering from a blood disorder that prevents proper clotting have the option of a new medication that may dramatically improve their health. There are estimated to be between 50,000 and 100, ...

A new analysis has concluded that Rituximab ( MabThera, Rituxan ), a drug commonly used to treat blood cancers, leads to treatment responses lasting at least five years in approximately one quarter of ...